5ANDREW J,BURGER,MD.A review of the renal and neurohormonal effects of B-type natriuretic peptide[J].Congest Heart Fail (CHF),2005,11 (1):30-38.
6YOUNG JB,YASUE H,MORITA E,et al.Vasodilation in the management of acute congestive heart failure (VMAC)[J].JAMA,2002,287:1531-1540.
7LINDSAY M,BURGER AJ,MARCUS LS,et al.Mortality and length of hospital stay in patients receiving dobutamine,milrinone,or nesiritide for acute decompensated heart Failure[C] //The English Science Conference of the American Heart Failure Association.2004.
8Burnett JC. Nesiritide: new hope for acute heart failure syndromes[J ] ? EHJ, 2005,7( Suppl B) : B25-B30.
9Colucci WS,Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure[J]. N Engl J Med,2000,343:246-253.
10Yaney CW,Sahzberg MT,Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSIONI Trial)[J].Am J Cardiol, 2004,94:595-601.
5Me Mutray JJ,Adamopoulos S,Anker SD,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 [ J ]. European Heart Journal ,2012,33 : 1792-1793.
6Cynthuia MB, Pasqualina S, RobertM, et al. Physiological, pathological, phar-macological, biochemical and hematologica factors affecting BNP and NT-pro BNP[ J]. Clinical Biochem- istry ,2008,41 ( 4-5 ) : 231-239.
